CAS: 114899-77-3; (1'R,6R,6Ar,7R,13S,14S,16R)-5-(Acetyloxy)-3',4',6,6A,7,13,14,16-Octahydro-6',8,14-Trihydroxy-7',9-Dimethoxy-4,10,23-Trimethylspiro[6,16-(Epithiopropanoxymethano)-7,13-Imino-12H-1,3-Dioxolo[7,8]Isoquino[3,2-B][3]Benzazocine-20,1'(2'H)-Isoquinolin]-19-One

该化合物是一种海洋衍生抗乳癌剂,它有选择性地抑制了分解的核糖核酸切除修补(TC-NER),它与DNA的细角相连,形成阻断转和导致双层断裂的吸附管道,导致易感染细胞的血吸附.它的机制对软组织沙眼和复发卵巢癌特别有效,由于它能够针对FUS-CHOP聚变蛋白,它明显地在分子脂瘤中活动. 创伤百科丁展示了一种有利于长期组织保留,允许间歇性剂量的药性皮肤特征. 它独特的行动方式和临床作用在特定恶性肿瘤治疗中突出其作用.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号114899-80-8 Ecteinascidin 770 | CAS号111726-43-3 5-(甲氧基甲氧基)苯并[d]... | CAS号533-31-3 芝麻酚 | CAS号244126-41-8 5-(methoxymetho... | CAS号488-17-5 3-甲基邻苯二酚 | CAS号244229-56-9 5-bromo-2-metho... | CAS号244126-25-8 5-bromo-2-metho... | CAS号244126-22-5 2-hydroxy-3-met... | CAS号244126-24-7 5-bromo-2-metho...

合成工艺路线路线简述

  • 合成目标产物 Trabectedin 主要起始原料 Ecteinascidin 770
  • (文献来源)合成步骤主要原料 Ecteinascidin 770
(1'R,6R,6Ar,7R,13S,14R,16R)-5-(Acetyloxy)-3',4',6,6A,7,13,14,16-octahydro-6'-Hydroxy-7',9-Dimethoxy-8-(Methoxymethoxy)-4,10,23-Trimethyl-19-Oxo-Spiro[6,16-(Epithiopropanoxymethano)-7,13-Imino-12H-1,3-Dioxolo[7,8]Isoquino[3,2-B][3]Benzazocine-20,1'(2'H)-Isoquinoline]-14-Carbonitrile置于三氟乙酸,Silver Nitrate体系中,用 四氢呋喃,水,乙腈 用作溶剂,化学反应 34.0H,反应生成他比特啶
参考文献: Process For The Preparation Of Ecteinascidin Derivative And Its Intermediate[fr] Procédé De Préparation D'Un Dérivé D'Ectéinascidine Et De Son Intermédiaire
标题: Process For The Preparation Of Ecteinascidin Derivative And Its Intermediate[fr] Procédé De Préparation D'Un Dérivé D'Ectéinascidine Et De Son Intermédiaire
摘要:本发明涉及一种改进的,工业上可行的trabectedin制备过程.本发明还涉及一种改进的,工业上可行的公式-A的trabectedin中间化合物制备过程.本发明使用成本更低的试剂,溶剂,并且工艺条件可以很容易地适用于商业规模.

专利信息


专利号:US-10973847-B2
优先权日:2017-06-30
标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

专利号:US-7820838-B2
优先权日:2002-01-29
标 题:Method for total synthesis of ecteinascidins and intermediate compounds thereof
发明人:FUKUYAMA TOHRU; KAN TOSHIYUKI
权利人:JAPAN SCIENCE & TECH AGENCY
摘要:An intermediate compound for total synthesis of ecteinascidins comprising, a compound represented by general formula 2 having thioether group at C4 site, and the substituent R 2 of N 12 site is trichloroethoxycarbonyl (Troc) to which various substituents can be introduced by mild condition, further having 10 members ring structure which can be converted to a ring of other numbered members.

专利号:US-2017283878-A1
优先权日:2015-12-11
标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
权利人:ACADEMIA SINICA
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

专利号:US-2024287041-A1
优先权日:2021-05-20
标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
发明人:BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.

专利号:WO-2007087220-A3
优先权日:2006-01-25
标题:The total synthesis of ecteinascidin 743 and derivatives thereof
发明人:DANISHEFSKY SAMUEL J; CHAN COLLIN
权利人:UNIV COLUMBIA; DANISHEFSKY SAMUEL J; CHAN COLLIN
摘要:This invention provides a method of synthesizing ecteinascidin 743 and derivatives. This invention also provides intermediate compounds and methods of treating tumors.

专利号:US-9227948-B2
优先权日:2012-06-19
标题:Process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[D][1,3]dioxol-4-yl)acetic acid derivatives
发明人:MUDDASANI PULLA REDDY; CHINTALAPUDI MANIKUMAR; NANNAPANENI VENKAIAH CHOWDARY
权利人:NATCO PHARMA LTD
摘要:Present invention relates to an improved and commercial process for the preparation of 2-sustituted-2-(6-(substituted)-7-methylbenzo[d][1,3]dioxol-4-yl)acetic acid derivatives of formula-I the above Formula I, XII, XIII, XV, wherein R 1 is a O-protecting group such as methoxymethyl, ethoxymethyl, trialkylsilyl, arylmethyl, tetrahydropyran-2-yl, allyl; X is hydroxyl, halogen, mesylate, triflate, tosylate, acetate; Y is oxygen atom, NH or sulfur atom; R 2 is C 1 -C 6 alkyl. 2,4-Dihydroxy-3-methylbenzaldehyde is selectively protected at C-4 position in the form of an ether compound of formula-XII, oxidized the aldehyde function to get the diol of formula-XIII, and condensed with ethyl glyoxalate under Casiraghi reaction conditions to get the compound of formula-XV. Compound of formula-XV is converted to compound of formula-I by conventional chemistry. Compounds of formula-I are key intermediates in the synthesis of ecteinascidines like trabectedin.
台州市科瑞生物技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.pharm-intermediates.com
企业联系电话:0576-88813233👤
📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
联系人:金崇光
电话:0576-88813233
手机:13396860566
传真:0576-88813233
邮箱:sales@pharm-intermediates.com
通信地址: 台州市开发大道东段288号
邮编: 318000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:台州市开发大道东段288号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
博瑞生物医药(苏州)股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.bright-gene.com
电话: 0512-0512-62551764 18013103761👤
📞博瑞生物医药(苏州)股份有限公司 ⚠️参考联系方式

销售电话:0512-0512-62551764 18013103761
邮箱:sales01@bright-gene.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Trabectedin: Reimbursement Recommendation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Oct. Report No.: PX0377. 2025 Sep. Report No.: PX0377r.
18:2021-2032. doi: 10.2147/DDDT.S451223.
4: Povo-Retana A, Landauro-Vera R, Alvarez-Lucena C, Cascante M, Boscá L. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy. Molecules. 2024 Jan 9;29(2):331. doi: 10.3390/molecules29020331. Erratum in: Molecules. 2025 Jun 05;30(11):2472. doi: 10.3390/molecules30112472.

合成参考文献


摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from
参考文献:10.1021/bi960306b
摘要:Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996 Oct 15;35(41):13303–9. doi: 10.1021/bi960306b.
参考文献:10.1021/jm990241l
摘要:Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem. 1999 Jul 15;42(14):2493–7. doi: 10.1021/jm990241l.
参考文献:10.1073/pnas.0510909103
摘要:Newman JC, Bailey AD, Weiner AM. Cockayne syndrome group B protein (CSB) plays a general role in chromatin maintenance and remodeling. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9613–8.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知